2007
Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J. Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice. Value in Health. In press.
2006
Gordois A, Nobes M, Toohey M, Russ G. Cost-effectiveness of sirolimus therapy with early cyclosporin withdrawal versus long-term cyclosporin therapy in Australia. Clinical Transplantation. 20:4, 526–536.
Burns T, Christova L, Cooper S, Harrison G, McKendrick J, Laugharne R, Obuaya T, McCreadie R, O’Brien S, Perrington S, Stephenson D. (2006) Maintenance antipsychotic medication patterns in outpatient schizophrenia patients: a naturalistic cohort study. Acta Psychiatrica Scandinavica 113: 126–134.
Bandana Saini, Carol Armour, Martha Brilliant, Sinthia Bosnic-Anticevich, Ines Krass, Lorraine Smith, Adam Gordois, Deborah Burton, Lynne Emmerton, Kay Stewart. Establishing effeciveness of a pharmacy based asthma care program. From Cell to Society 5. 5th Biennial Health Research Conference, 9–10 November 2006. Leura, NSW. Poster presentation.
Davey P. Pricing reimbursement and health outcomes. Regional Conference in Cost-effective Healthcare 2006, 30–31 October 2006. Singapore. Podium presentation.
Adams J, LeReun C, Crowley S, Eggleston A, Schrover R. A carer’s perspective on the value of schizophrenia-related health states using the Assessment of Quality of Life Questionnaire and the EUROQoL (EQ5D). ISPOR 9th Annual European Congress, 28–31 October 2006, Copenhagen, Denmark. Podium presentation.
Walters N, Gordois A, Brown A, Lindsay P, Gonzalo F, Comas S. Quantifying the impact of fear of hypoglycaemia on quality of life. ISPOR 9th Annual European Congress, 28–31 October 2006, Copenhagen, Denmark. Poster presentation.
Pascoe K, McDonald-Everett CM, FitzGerald P, Yurgin NR, Secnik K. The efficacy of insulin glargine compared to other injectable therapies—a meta-analysis of clinical outcomes in insulin naïve type 2 diabetes patients. ISPOR 9th Annual European Congress, 28–31 October 2006, Copenhagen, Denmark. Poster presentation.
Davey P. Recent policy initiatives in the Australian national reimbursement system that have reduced cost dramatically. ISPOR 11th Annual International Meeting, 20–24 May 2006. Philadelphia, Pennsylvania, USA. Podium presentation.
Montogomery B, Christova L, Mudge M, Davey P. Use patterns and outcomes associated with typical depot antipsychotic agents in the Schizophrenia Care Assessment Program (SCAP) in AustraliaISPOR 11th Annual International Meeting, 20–24 May 2006. Philadelphia, Pennsylvania, USA. Podium presentation.
Price N, Davey P, Mudge M, Fitzgerald B, Rajan N, Montgomery B. Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia. ISPOR 11th Annual International Meeting, 20–24 May 2006. Philadelphia, Pennsylvania, USA. Poster presentation.
Davey P. Strategic management. Pharmaceutical generics—a changing playing field. 4th Annual Pharma Marketing & Sales Congress, 3–4 May 2006. North Ryde, NSW, Australia. Podium presentation.
Adams J, Nand V, Le Reun C, Mudge M, Crowley S, Eggleston A, Schrover R, Brown A. The impact of schizophrenia on caregivers: burden of illness and quality of life. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Davey P, Cordony A, Rajan N, Arora B, Pavlakis N. Cost-effectiveness of pemetrexed plus cisplatin versus cisplatin alone in the treatment of malignant pleural mesothelioma. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Brown A, Aristides M, FitzGerald P, Liepa A, Boyer M, Clarke S. Patient preference and willingnesss-to-pay for pemetrexed versus docetaxel in the second-line treatment of advanced non-small cell lung cancer: a discrete choice conjoint analysis. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Price N, Davey P, Mudge M, FitzGerald P, Rajan N, Montgomery B. Cost-effectiveness of olanzapine versus lithium for the prevention of relapse in bipolar I disorder in Australia ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Adams J, Le Reun C, Crowley S, Nand V, Eggleston A, Schrover R. Valuation of schizophrenia related health states by the general population using the assessment of quality of life questionnaire, time trade-off and visual analogue scales. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Adams J, Nand V, Le Reun C, Mudge M, Crowley S, Eggleston A, Schrover R, Brown A. Assessing the health and economic impact of schizophrenia on carers: a pilot study. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Adams J, Nand V, Le Reun C, Crowley S, Eggleston A, Schrover R, Brown A. Preference and willingness-to-pay for the treatment of schizophrenia from a carer’s perspective. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.
Aldridge G, Frost M, Le Reun C, Lynch M, Davey P, Napier-Flood F. Efficacy of botulinum toxin type A (BoNTA) in the treatment of adult spasticity: a meta-analysis of response rate using individual patient data. ISPOR 2nd Asia-Pacific conference, Shanghai, China 5–7 March 2006. Poster presentation.